E
Medicenna Therapeutics Corp.
MDNAF
$0.744
-$0.016-2.11%
E
Sell
1/10/2025Downgrade
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 1/10/2025 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 141.9% from -$1.7M to -$4.12M, EBIT declined 37.25% from -$2.95M to -$4.05M, and earnings per share declined from -$0.0361 to -$0.0397.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 1/10/2025 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 141.9% from -$1.7M to -$4.12M, EBIT declined 37.25% from -$2.95M to -$4.05M, and earnings per share declined from -$0.0361 to -$0.0397.
D
Sell
9/9/2024Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E+ on 9/9/2024 due to a large increase in the total return index, solvency index and growth index. The quick ratio increased from 1.3 to 2.43, earnings per share increased from -$0.1481 to -$0.0361, and operating cash flow increased 52.66% from -$3.59M to -$1.7M.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E+ on 9/9/2024 due to a large increase in the total return index, solvency index and growth index. The quick ratio increased from 1.3 to 2.43, earnings per share increased from -$0.1481 to -$0.0361, and operating cash flow increased 52.66% from -$3.59M to -$1.7M.
E
Sell
3/28/2024Downgrade
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 3/28/2024 due to a decline in the solvency index and valuation index.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 3/28/2024 due to a decline in the solvency index and valuation index.
D
Sell
3/13/2024Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E+ on 3/13/2024 due to an increase in the volatility index and total return index.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E+ on 3/13/2024 due to an increase in the volatility index and total return index.
E
Sell
2/22/2024Downgrade
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 2/22/2024 due to a decline in the growth index, solvency index and volatility index. The quick ratio declined from 7.03 to 4.78, earnings per share declined from -$0.0399 to -$0.0525, and operating cash flow declined 1.23% from -$2.92M to -$2.96M.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 2/22/2024 due to a decline in the growth index, solvency index and volatility index. The quick ratio declined from 7.03 to 4.78, earnings per share declined from -$0.0399 to -$0.0525, and operating cash flow declined 1.23% from -$2.92M to -$2.96M.
D
Sell
2/15/2024Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E+ on 2/15/2024 due to an increase in the total return index, volatility index and valuation index.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E+ on 2/15/2024 due to an increase in the total return index, volatility index and valuation index.
E
Sell
3/14/2023Downgrade
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 03/14/2023.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Medicenna Therapeutics Corp. (MDNA) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
Medicenna Therapeutics Corp. (MDNA) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Medicenna Therapeutics Corp. (MDNA) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, total return index and valuation index. Earnings per share declined from -$0.0108 to -$0.0121.
Medicenna Therapeutics Corp. (MDNA) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index, total return index and valuation index. Earnings per share declined from -$0.0108 to -$0.0121.
D
Sell
12/22/2022Downgrade
Medicenna Therapeutics Corp. (MDNA) was downgraded to D- from D on 12/22/2022 due to a decline in the total return index and volatility index.
Medicenna Therapeutics Corp. (MDNA) was downgraded to D- from D on 12/22/2022 due to a decline in the total return index and volatility index.
D
Sell
12/7/2022Upgraded
Medicenna Therapeutics Corp. (MDNA) was upgraded to D from D- on 12/7/2022 due to an increase in the volatility index and valuation index.
Medicenna Therapeutics Corp. (MDNA) was upgraded to D from D- on 12/7/2022 due to an increase in the volatility index and valuation index.
D
Sell
11/21/2022Downgrade
Medicenna Therapeutics Corp. (MDNA) was downgraded to D- from D on 11/21/2022 due to a decline in the total return index, volatility index and valuation index.
Medicenna Therapeutics Corp. (MDNA) was downgraded to D- from D on 11/21/2022 due to a decline in the total return index, volatility index and valuation index.
D
Sell
11/1/2022Upgraded
Medicenna Therapeutics Corp. (MDNA) was upgraded to D from D- on 11/1/2022 due to an increase in the volatility index and valuation index.
Medicenna Therapeutics Corp. (MDNA) was upgraded to D from D- on 11/1/2022 due to an increase in the volatility index and valuation index.
D
Sell
10/17/2022Downgrade
Medicenna Therapeutics Corp. (MDNA) was downgraded to D- from D on 10/17/2022 due to a noticeable decline in the volatility index, total return index and solvency index.
Medicenna Therapeutics Corp. (MDNA) was downgraded to D- from D on 10/17/2022 due to a noticeable decline in the volatility index, total return index and solvency index.
D
Sell
5/5/2022Upgraded
Medicenna Therapeutics Corp. (MDNA) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and total return index.
Medicenna Therapeutics Corp. (MDNA) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index and total return index.
D
Sell
4/20/2022Downgrade
Medicenna Therapeutics Corp. (MDNA) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index.
Medicenna Therapeutics Corp. (MDNA) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index.
D
Sell
11/15/2021Upgraded
Medicenna Therapeutics Corp. (MDNA) was upgraded to D from D- on 11/15/2021 due to an increase in the growth index.
Medicenna Therapeutics Corp. (MDNA) was upgraded to D from D- on 11/15/2021 due to an increase in the growth index.
D
Sell
11/8/2021Downgrade
Medicenna Therapeutics Corp. (MDNA) was downgraded to D- from D on 11/8/2021 due to a major decline in the total return index, growth index and volatility index. Operating cash flow declined 118.16% from -$1.71M to -$3.72M, EBIT declined 12.2% from -$4.51M to -$5.06M, and earnings per share declined from -$0.088 to -$0.0971.
Medicenna Therapeutics Corp. (MDNA) was downgraded to D- from D on 11/8/2021 due to a major decline in the total return index, growth index and volatility index. Operating cash flow declined 118.16% from -$1.71M to -$3.72M, EBIT declined 12.2% from -$4.51M to -$5.06M, and earnings per share declined from -$0.088 to -$0.0971.
D
Sell
5/1/2020Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, volatility index and growth index.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, volatility index and growth index.
D
Sell
2/18/2020Downgrade
Medicenna Therapeutics Corp. (MDNAF) was downgraded to D- from D on 2/18/2020 due to a decline in the growth index. Operating cash flow declined 29.74% from -$1.22M to -$1.58M, EBIT declined 27.17% from -$1.43M to -$1.82M, and earnings per share declined from -$0.0501 to -$0.0545.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to D- from D on 2/18/2020 due to a decline in the growth index. Operating cash flow declined 29.74% from -$1.22M to -$1.58M, EBIT declined 27.17% from -$1.43M to -$1.82M, and earnings per share declined from -$0.0501 to -$0.0545.
D
Sell
11/19/2019Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D from D- on 11/19/2019 due to an increase in the total return index and volatility index.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D from D- on 11/19/2019 due to an increase in the total return index and volatility index.
D
Sell
11/6/2019Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E+ on 11/6/2019 due to an increase in the volatility index and valuation index.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E+ on 11/6/2019 due to an increase in the volatility index and valuation index.
E
Sell
10/2/2019Downgrade
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 10/2/2019 due to a decline in the efficiency index, valuation index and solvency index. Total capital declined 30.63% from $1.96M to $1.36M, and net income declined 22.63% from -$789.1 to -$967.7.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 10/2/2019 due to a decline in the efficiency index, valuation index and solvency index. Total capital declined 30.63% from $1.96M to $1.36M, and net income declined 22.63% from -$789.1 to -$967.7.
D
Sell
6/13/2019Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E+ on 6/13/2019 due to an increase in the volatility index and total return index.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E+ on 6/13/2019 due to an increase in the volatility index and total return index.
E
Sell
2/15/2019Downgrade
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 2/15/2019 due to a major decline in the growth index, efficiency index and total return index. EBIT declined 90.83% from -$680.2 to -$1.3M, net income declined 90.11% from -$686.7 to -$1.31M, and earnings per share declined from -$0.0279 to -$0.0522.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E+ from D- on 2/15/2019 due to a major decline in the growth index, efficiency index and total return index. EBIT declined 90.83% from -$680.2 to -$1.3M, net income declined 90.11% from -$686.7 to -$1.31M, and earnings per share declined from -$0.0279 to -$0.0522.
D
Sell
1/11/2019Downgrade
Medicenna Therapeutics Corp. (MDNAF) was downgraded to D- from D on 1/11/2019 due to a decline in the total return index and volatility index.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to D- from D on 1/11/2019 due to a decline in the total return index and volatility index.
D
Sell
12/27/2018Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D from D- on 12/27/2018 due to a substantial increase in the growth index and efficiency index. Operating cash flow increased 34.5% from -$1.83M to -$1.2M, EBIT increased 16.38% from -$813.4 to -$680.2, and earnings per share increased from -$0.0327 to -$0.0279.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D from D- on 12/27/2018 due to a substantial increase in the growth index and efficiency index. Operating cash flow increased 34.5% from -$1.83M to -$1.2M, EBIT increased 16.38% from -$813.4 to -$680.2, and earnings per share increased from -$0.0327 to -$0.0279.
D
Sell
6/5/2018Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E on 6/5/2018 due to an increase in the valuation index.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to D- from E on 6/5/2018 due to an increase in the valuation index.
E
Sell
3/21/2018Downgrade
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E from E+ on 3/21/2018 due to a noticeable decline in the volatility index and total return index.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E from E+ on 3/21/2018 due to a noticeable decline in the volatility index and total return index.
E
Sell
3/6/2018Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to E+ from E on 3/6/2018 due to a large increase in the volatility index and total return index.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to E+ from E on 3/6/2018 due to a large increase in the volatility index and total return index.
E
Sell
3/1/2018Upgraded
Medicenna Therapeutics Corp. (MDNAF) was upgraded to E from E- on 03/01/2018.
Medicenna Therapeutics Corp. (MDNAF) was upgraded to E from E- on 03/01/2018.
E
Sell
2/9/2018Downgrade
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E- from E on 2/9/2018 due to a large decline in the volatility index.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E- from E on 2/9/2018 due to a large decline in the volatility index.
E
Sell
12/13/2017None
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E from U on 12/13/2017.
Medicenna Therapeutics Corp. (MDNAF) was downgraded to E from U on 12/13/2017.
OTC PK
03/17/2025 3:59PM Eastern
Quotes delayed
